BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 25486497)

  • 1. Promoter methylation of protocadherin8 is an independent prognostic factor for biochemical recurrence of early-stage prostate cancer.
    Niu WB; Gui SL; Lin YL; Fu XL; Ma JG; Li WP
    Med Sci Monit; 2014 Dec; 20():2584-9. PubMed ID: 25486497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aberrant Promoter Methylation of Protocadherin8 (PCDH8) in Serum is a Potential Prognostic Marker for Low Gleason Score Prostate Cancer.
    Lin YL; Li YL; Ma JG
    Med Sci Monit; 2017 Oct; 23():4895-4900. PubMed ID: 29026066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aberrant methylation of protocadherin 17 and its clinical significance in patients with prostate cancer after radical prostatectomy.
    Lin YL; Xie PG; Wang L; Ma JG
    Med Sci Monit; 2014 Aug; 20():1376-82. PubMed ID: 25091018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aberrant methylation of PCDH10 predicts worse biochemical recurrence-free survival in patients with prostate cancer after radical prostatectomy.
    Wang L; Xie PG; Lin YL; Ma JG; Li WP
    Med Sci Monit; 2014 Aug; 20():1363-8. PubMed ID: 25086586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical significance of protocadherin 8 (PCDH8) promoter methylation in non-muscle invasive bladder cancer.
    Lin YL; Wang YL; Ma JG; Li WP
    J Exp Clin Cancer Res; 2014 Aug; 33(1):68. PubMed ID: 25927589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multicenter clinical validation of PITX2 methylation as a prostate specific antigen recurrence predictor in patients with post-radical prostatectomy prostate cancer.
    Bañez LL; Sun L; van Leenders GJ; Wheeler TM; Bangma CH; Freedland SJ; Ittmann MM; Lark AL; Madden JF; Hartman A; Weiss G; Castaños-Vélez E
    J Urol; 2010 Jul; 184(1):149-56. PubMed ID: 20478579
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic Value of Protocadherin10 (PCDH10) Methylation in Serum of Prostate Cancer Patients.
    Deng QK; Lei YG; Lin YL; Ma JG; Li WP
    Med Sci Monit; 2016 Feb; 22():516-21. PubMed ID: 26881880
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of protocadherin8: Function as a tumor suppressor in hypopharyngeal carcinoma.
    Li Y; Liu C; Wang Z; Hu G
    Cancer Biomark; 2018; 22(3):495-502. PubMed ID: 29865037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High BIRC7 Expression Might Be an Independent Prognostic Indicator of Poor Recurrence-Free Survival in Patients With Prostate Cancer.
    Yang Y; Sun P; Xu W; Xia W
    Technol Cancer Res Treat; 2018 Jan; 17():1533033818809694. PubMed ID: 30376767
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aberrant methylation of CDH13 is a potential biomarker for predicting the recurrence and progression of non muscle invasive bladder cancer.
    Lin YL; Xie PG; Ma JG
    Med Sci Monit; 2014 Sep; 20():1572-7. PubMed ID: 25196672
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic signature of protocadherin 10 methylation in curatively resected pathological stage I non-small-cell lung cancer.
    Harada H; Miyamoto K; Yamashita Y; Taniyama K; Mihara K; Nishimura M; Okada M
    Cancer Med; 2015 Oct; 4(10):1536-46. PubMed ID: 26276761
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aberrant promoter methylation of the cadherin 13 gene in serum and its relationship with clinicopathological features of prostate cancer.
    Wang L; Lin YL; Li B; Wang YZ; Li WP; Ma JG
    J Int Med Res; 2014 Oct; 42(5):1085-92. PubMed ID: 25015764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High promoter methylation levels of APC predict poor prognosis in sextant biopsies from prostate cancer patients.
    Henrique R; Ribeiro FR; Fonseca D; Hoque MO; Carvalho AL; Costa VL; Pinto M; Oliveira J; Teixeira MR; Sidransky D; Jerónimo C
    Clin Cancer Res; 2007 Oct; 13(20):6122-9. PubMed ID: 17947477
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DNA methylation of the PITX2 gene promoter region is a strong independent prognostic marker of biochemical recurrence in patients with prostate cancer after radical prostatectomy.
    Weiss G; Cottrell S; Distler J; Schatz P; Kristiansen G; Ittmann M; Haefliger C; Lesche R; Hartmann A; Corman J; Wheeler T
    J Urol; 2009 Apr; 181(4):1678-85. PubMed ID: 19233404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validation study of genes with hypermethylated promoter regions associated with prostate cancer recurrence.
    Stott-Miller M; Zhao S; Wright JL; Kolb S; Bibikova M; Klotzle B; Ostrander EA; Fan JB; Feng Z; Stanford JL
    Cancer Epidemiol Biomarkers Prev; 2014 Jul; 23(7):1331-9. PubMed ID: 24718283
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preoperative combined nested reverse transcriptase polymerase chain reaction for prostate-specific antigen and prostate-specific membrane antigen does not correlate with pathologic stage or biochemical failure in patients with localized prostate cancer undergoing radical prostatectomy.
    Thomas J; Gupta M; Grasso Y; Reddy CA; Heston WD; Zippe C; Dreicer R; Kupelian PA; Brainard J; Levin HS; Klein EA
    J Clin Oncol; 2002 Aug; 20(15):3213-8. PubMed ID: 12149293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PITX2 methylation: a novel and effective biomarker for monitoring biochemical recurrence risk of prostate cancer.
    Jiang Q; Xie M; He M; Yan F; Chen M; Xu S; Zhang X; Shen P
    Medicine (Baltimore); 2019 Jan; 98(1):e13820. PubMed ID: 30608394
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy.
    Rosenbaum E; Hoque MO; Cohen Y; Zahurak M; Eisenberger MA; Epstein JI; Partin AW; Sidransky D
    Clin Cancer Res; 2005 Dec; 11(23):8321-5. PubMed ID: 16322291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aberrant Protocadherin17 (PCDH17) Methylation in Serum is a Potential Predictor for Recurrence of Early-Stage Prostate Cancer Patients After Radical Prostatectomy.
    Lin YL; Deng QK; Wang YH; Fu XL; Ma JG; Li WP
    Med Sci Monit; 2015 Dec; 21():3955-690. PubMed ID: 26683656
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multigene methylation analysis for detection and staging of prostate cancer.
    Enokida H; Shiina H; Urakami S; Igawa M; Ogishima T; Li LC; Kawahara M; Nakagawa M; Kane CJ; Carroll PR; Dahiya R
    Clin Cancer Res; 2005 Sep; 11(18):6582-8. PubMed ID: 16166436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.